Sixera pharma news
News
News
Sixera Pharma Receives Rare Pediatric Disease Designation (RPDD) from FDA for SXR1096 for treatment of Netherton syndrome
Stockholm, July 5, 2022. The Swedish biotech company, Sixera Pharma (”Sixera”) today announced that the US Food and Drug Administration (FDA) has granted rare pediatric
July 5, 2022
No Comments
News
Sixera initiates its first clinical trial on SXR1096 in Netherton Syndrome
with the potential to be the first available treatment of the rare and serious skin disease Netherton syndrome Stockholm, December 7, 2021. The Swedish biotech
December 7, 2021
No Comments
News
The start of something new
Welcome to our newly launched website were we will make it possible for you to follow our work and take part of insights from our
June 15, 2018
No Comments
The Project
